AU2256801A - Methods and compositions for use in the treatment of filovirus mediated disease conditions - Google Patents

Methods and compositions for use in the treatment of filovirus mediated disease conditions

Info

Publication number
AU2256801A
AU2256801A AU22568/01A AU2256801A AU2256801A AU 2256801 A AU2256801 A AU 2256801A AU 22568/01 A AU22568/01 A AU 22568/01A AU 2256801 A AU2256801 A AU 2256801A AU 2256801 A AU2256801 A AU 2256801A
Authority
AU
Australia
Prior art keywords
compositions
treatment
methods
mediated disease
disease conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22568/01A
Inventor
Stephen Y. CHAN
Mark A. Goldsmith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU2256801A publication Critical patent/AU2256801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU22568/01A 1999-12-09 2000-12-07 Methods and compositions for use in the treatment of filovirus mediated disease conditions Abandoned AU2256801A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17000499P 1999-12-09 1999-12-09
US60170004 1999-12-09
US23742100P 2000-10-02 2000-10-02
US60237421 2000-10-02
PCT/US2000/033403 WO2001041784A1 (en) 1999-12-09 2000-12-07 Methods and compositions for use in the treatment of filovirus mediated disease conditions

Publications (1)

Publication Number Publication Date
AU2256801A true AU2256801A (en) 2001-06-18

Family

ID=26865593

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22568/01A Abandoned AU2256801A (en) 1999-12-09 2000-12-07 Methods and compositions for use in the treatment of filovirus mediated disease conditions

Country Status (2)

Country Link
AU (1) AU2256801A (en)
WO (1) WO2001041784A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156853A2 (en) * 2007-06-20 2008-12-24 The Board Of Regents Of The University Of Texas System Inhibition of filovirus entry into cells and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications

Also Published As

Publication number Publication date
WO2001041784A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU5788300A (en) Medical treatment method and kit
AU5309400A (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU4511201A (en) Compositions and methods for the induction and treatment of retinal detachments
AU1878201A (en) Composition for the treatment of damaged tissue
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
IL147410A0 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2420101A (en) Method and composition for the treatment of pain
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU2256801A (en) Methods and compositions for use in the treatment of filovirus mediated disease conditions
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU3061199A (en) Skin treatment compositions and the use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase